1-[4-(benzyloxy)-5-bromo-2-methylphenyl]ethanone | 957774-00-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[4-(benzyloxy)-5-bromo-2-methylphenyl]ethanone
• 英文别名: 1-(5-bromo-2-methyl-4-phenylmethoxyphenyl)ethanone
• CAS: 957774-00-4
• 化学式: C₁₆H₁₅BrO₂
• 分子量: 319.198
• InChiKey: HYMAWBDNJPLLIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[4-(benzyloxy)-5-bromo-2-methylphenyl]ethanone 在 氢氧化钾 、 sodium hypochlorite 、 盐酸 、 水 作用下， 以 水 为溶剂， 反应 1.0h， 生成 4-(苄氧基)-5-溴-2-甲基苯甲酸
  参考文献：
  名称：

  C-PHENYL 1-THIOGLUCITOL COMPOUND

  摘要：

  公开号：

  EP2036901B1
• 作为产物：
  描述：

  溴甲苯 在 四丁基碘化铵 Oxone 、 potassium carbonate 、 sodium bromide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.5h， 生成 1-[4-(benzyloxy)-5-bromo-2-methylphenyl]ethanone
  参考文献：
  名称：

  WO2007/136116

  摘要：

  公开号：

文献信息

• C-PHENYL GLYCITOL COMPOUND
  申请人：Kakinuma Hiroyuki

  公开号：US20100022460A1

  公开（公告）日：2010-01-28

  Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof wherein R 1 and R 2 are the same or different and represent a hydrogen atom, a hydroxyl group, a C 1-6 alkyl group, a C 1-6 alkoxy group or a halogen atom, R 3 is a hydrogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or a halogen atom, Y is a C 1-6 alkylene group, —O—(CH 2 )n— (n is an integer of 1 to 4) or a C 2-6 alkenylene group, provided that when Z is —NHC(═NH)NH 2 or —NHCON(R B )R C , n is not 1, Z is —CONHR A , —NHC(═NH)NH 2 or —NHCON(R B )R C ,

  提供的是一种新型C-苯基甘露醇化合物，可以作为预防或治疗糖尿病的药物，通过抑制SGLT1活性和SGLT2活性，从而表现出抑制葡萄糖吸收和尿液葡萄糖排泄的作用。该化合物表示为以下式子（I）的C-苯基甘露醇化合物，或其药学上可接受的盐或水合物，其中R1和R2相同或不同，表示氢原子、羟基、C1-6烷基、C1-6烷氧基或卤素原子，R3表示氢原子、C1-6烷基、C1-6烷氧基或卤素原子，Y表示C1-6烷基、-O-(CH2)n-（n为1至4的整数）或C2-6烯基烷基，但当Z为-NHC（=NH）NH2或-NHCON（RB）RC时，n不为1，Z为CONHRA，-NHC（=NH）NH2或-NHCON（RB）RC。
• 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE
  申请人：Kakinuma Hiroyuki

  公开号：US20100069460A1

  公开（公告）日：2010-03-18

  A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like: or a pharmaceutically acceptable salt thereof or a hydrate thereof, or a pharmaceutical preparation comprising the same as an active ingredient is useful as a novel type of prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which inhibits both SGLT1 and SGLT2 activities to achieve not only suppression of glucose absorption from the digestive tract but also excretion of urinary sugars.

  一种由公式（I）或类似物表示的1-苯基1-硫代-D-葡萄糖醇化合物，或其药学上可接受的盐或水合物，或包含其作为活性成分的制药制剂，可用作一种新型的预防或治疗糖尿病、糖尿病相关疾病或糖尿病并发症的药物。该药物不仅抑制消化道中的葡萄糖吸收，还能促进尿糖的排泄，通过同时抑制SGLT1和SGLT2活性来实现。
• C-phenyl glycitol compound
  申请人：Taisho Pharmaceutical Co., Ltd

  公开号：US07973012B2

  公开（公告）日：2011-07-05

  Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof wherein R1 and R2 are the same or different and represent a hydrogen atom, a hydroxyl group, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, R3 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, Y is a C1-6 alkylene group, —O—(CH2)n- (n is an integer of 1 to 4) or a C2-6 alkenylene group, provided that when Z is —NHC(═NH)NH2 or —NHCON(RB)RC, n is not 1, Z is —CONHRA, —NHC(═NH)NH2 or —NHCON(RB)RC,

  提供一种新型的C-苯基甘露醇化合物，可以作为预防或治疗糖尿病的药物，通过抑制SGLT1活性和SGLT2活性，从而表现出葡萄糖吸收抑制作用和尿糖排泄作用。所述C-苯基甘露醇化合物如下式（I）所示，或其药学上可接受的盐或水合物，其中R1和R2相同或不同，表示氢原子、羟基、C1-6烷基、C1-6烷氧基或卤素原子，R3表示氢原子、C1-6烷基、C1-6烷氧基或卤素原子，Y表示C1-6烷基、—O—（CH2）n-（n是1到4的整数）或C2-6烯基烷基，但当Z为—NHC（═NH）NH2或—NHCON（RB）RC时，n不为1，Z为—CONHRA、—NHC（═NH）NH2或—NHCON（RB）RC。
• C-phenyl 1-thioglucitol compound
  申请人：Taisho Pharmaceutical Co., Ltd

  公开号：US08115017B2

  公开（公告）日：2012-02-14

  C-phenyl 1-thioglucitol compounds of the following formula (I) or pharmaceutically acceptable salts thereof or hydrates thereof: [wherein X represents a hydrogen atom or a C1-6 alkyl group, Y represents a C1-6 alkylene group or —O—(CH2)n- (wherein n represents an integer of 1 to 5), and Z represents —CONHRA or —NHCONHRB (provided that when Z represents —NHCONHRB, n is not 1), wherein RA represents a C1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH2, and RB represents a hydrogen atom or a C1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH2] are useful as prophylactic or therapeutic agents for diabetes, because of their suppressive effect on sugar (e.g., glucose) absorption through inhibition of SGLT1 activity, or alternatively, because of their suppressive effect on sugar (e.g., glucose) absorption and excretory effect on urinary sugars through inhibition of both SGLT1 and SGLT2 activities.

  以下式(I)的C-苯基1-硫基葡萄糖醇化合物或其药物可接受的盐或水合物：[其中X代表氢原子或C1-6烷基，Y代表C1-6烷基或-O-(CH2)n-（其中n表示1至5的整数），Z代表—CONHRA或—NHCONHRB（但当Z代表—NHCONHRB时，n不为1），其中RA代表C1-6烷基，其被1到3个从羟基和—CONH2组成的取代基所取代，而RB代表氢原子或C1-6烷基，其被1到3个从羟基和—CONH2组成的取代基所取代]，因其对通过抑制SGLT1活性的糖（例如葡萄糖）吸收的抑制作用或者对通过抑制SGLT1和SGLT2活性的糖（例如葡萄糖）吸收和尿糖排泄作用的抑制作用，可用作糖尿病的预防或治疗剂。
• EP2103607
  申请人：——

  公开号：——

  公开（公告）日：——